| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Laune. Clozapine, cognition, and schizophrenia. The British journal of psychiatry : the journal of mental science. vol 162. 1993-06-03. PMID:8481757. |
clozapine, cognition, and schizophrenia. |
1993-06-03 |
2023-08-12 |
Not clear |
| D Jonsson, N Zethraeus, M Mansfield, J Wålinde. [Clozapine treatment of patients with schizophrenia. Great improvements with regard to symptoms and social life]. Lakartidningen. vol 90. issue 16. 1993-06-03. PMID:8483355. |
[clozapine treatment of patients with schizophrenia. |
1993-06-03 |
2023-08-12 |
Not clear |
| M Davidson, R S Kahn, R G Stern, J Hirschowitz, S Apter, P Knott, K L Davi. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry research. vol 46. issue 2. 1993-06-03. PMID:8483974. |
treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. |
1993-06-03 |
2023-08-12 |
Not clear |
| M Davidson, R S Kahn, R G Stern, J Hirschowitz, S Apter, P Knott, K L Davi. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry research. vol 46. issue 2. 1993-06-03. PMID:8483974. |
these findings suggest that clozapine's effect on da turnover is small and that clozapine may be effective in treatment-refractory schizophrenia by mechanisms other than, or in addition to, dopamine receptor blockade. |
1993-06-03 |
2023-08-12 |
Not clear |
| M W Jann, S R Grimsley, E C Gray, W H Chan. Pharmacokinetics and pharmacodynamics of clozapine. Clinical pharmacokinetics. vol 24. issue 2. 1993-04-16. PMID:8453823. |
the introduction of clozapine has given clinicians a unique agent for treating patients with schizophrenia that is refractory to other neuroleptics. |
1993-04-16 |
2023-08-12 |
Not clear |
| M W Jann, S R Grimsley, E C Gray, W H Chan. Pharmacokinetics and pharmacodynamics of clozapine. Clinical pharmacokinetics. vol 24. issue 2. 1993-04-16. PMID:8453823. |
only a few studies have examined the pharmacokinetics of clozapine in patients with schizophrenia. |
1993-04-16 |
2023-08-12 |
Not clear |
| M W Jann, S R Grimsley, E C Gray, W H Chan. Pharmacokinetics and pharmacodynamics of clozapine. Clinical pharmacokinetics. vol 24. issue 2. 1993-04-16. PMID:8453823. |
careful patient selection and monitoring are required when clozapine therapy is used in patients with schizophrenia. |
1993-04-16 |
2023-08-12 |
Not clear |
| N R Swerdlow, M A Geye. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacology, biochemistry, and behavior. vol 44. issue 3. 1993-04-12. PMID:8451276. |
clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. |
1993-04-12 |
2023-08-12 |
rat |
| M Laune. Clozapine. British journal of hospital medicine. vol 49. issue 1. 1993-03-17. PMID:8431727. |
clozapine is an atypical agent for intractable schizophrenia which was introduced into the uk at the beginning of 1990. |
1993-03-17 |
2023-08-12 |
Not clear |
| B Blanz, M H Schmid. Clozapine for schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry. vol 32. issue 1. 1993-03-10. PMID:8428878. |
clozapine for schizophrenia. |
1993-03-10 |
2023-08-12 |
Not clear |
| L M Davies, M F Drummon. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. The British journal of psychiatry : the journal of mental science. vol 162. 1993-02-26. PMID:8425137. |
an analysis was conducted on the basis of available data to assess the economic consequences of clozapine therapy for people with moderate to severe schizophrenia in long-stay institutions or staffed group homes, with a view to providing an estimate of the likely costs and benefits of the drug. |
1993-02-26 |
2023-08-12 |
Not clear |
| L M Davies, M F Drummon. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. The British journal of psychiatry : the journal of mental science. vol 162. 1993-02-26. PMID:8425137. |
a prospective health economic study with clozapine in the management of schizophrenia would be desirable to confirm these results. |
1993-02-26 |
2023-08-12 |
Not clear |
| T E Goldberg, R D Greenberg, S J Griffin, J M Gold, J E Kleinman, D Pickar, S C Schulz, D R Weinberge. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. The British journal of psychiatry : the journal of mental science. vol 162. 1993-02-26. PMID:8425138. |
the effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. |
1993-02-26 |
2023-08-12 |
Not clear |
| S L Mason, G P Reynold. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. European journal of pharmacology. vol 221. issue 2-3. 1992-12-22. PMID:1426017. |
clozapine demonstrated the highest affinity; all other antipsychotics studied demonstrated pk(i) values below 6.0 5-ht1a receptors are found on cortical glutamatergic neurons, a dysfunction of which may occur in schizophrenia. |
1992-12-22 |
2023-08-11 |
human |
| S I Wolk, C J Dougla. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. The Journal of clinical psychiatry. vol 53. issue 10. 1992-12-11. PMID:1358876. |
clozapine has gained acceptance as an antipsychotic in treatment-resistant schizophrenia. |
1992-12-11 |
2023-08-11 |
Not clear |
| T Suppes, S L McElroy, J Gilbert, E C Dessain, J O Col. Clozapine in the treatment of dysphoric mania. Biological psychiatry. vol 32. issue 3. 1992-12-08. PMID:1420643. |
this remarkable improvement in a severely ill group of patients suggests that clozapine may have utility in the treatment of bipolar disorder as well as schizophrenia. |
1992-12-08 |
2023-08-11 |
Not clear |
| E J Collins, P Lalonde, B D Jones, D Addington, D J MacCrimmon, G W MacEwan, M D Teeha. Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelines. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 37. issue 7. 1992-12-08. PMID:1423146. |
clozapine in the treatment of refractory schizophrenia: canadian policies and clinical guidelines. |
1992-12-08 |
2023-08-11 |
Not clear |
| E J Collins, P Lalonde, B D Jones, D Addington, D J MacCrimmon, G W MacEwan, M D Teeha. Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelines. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 37. issue 7. 1992-12-08. PMID:1423146. |
clozapine is an atypical neuroleptic agent that has recently become available in canada with potential clinical efficacy in the treatment of refractory schizophrenia, and in patients with schizophrenia neurologically intolerant to conventional neuroleptics. |
1992-12-08 |
2023-08-11 |
Not clear |
| J M Kan. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. The British journal of psychiatry. Supplement. issue 17. 1992-12-02. PMID:1418888. |
clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. |
1992-12-02 |
2023-08-11 |
Not clear |
| D Y. [The correlation between clozapine saliva level and clinical response as well as side effect in patient with schizophrenia]. Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry. vol 25. issue 3. 1992-11-04. PMID:1356717. |
[the correlation between clozapine saliva level and clinical response as well as side effect in patient with schizophrenia]. |
1992-11-04 |
2023-08-11 |
Not clear |